A Pilot Comparison Study of Vibrating Mesh Versus Standard Jet Nebuliser for Bronchodilator Delivery in COPD
Chronic Obstructive Pulmonary Disease (COPD)
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease (COPD)
Eligibility Criteria
Inclusion Criteria:
- Hospital Inpatients admitted with an acute exacerbation of COPD
- Age >40
- COPD Stage 2-4 moderate to severe (FEV1/FVC <0.70;FEV1<80%)
- History of physician-diagnosed COPD
- COPD exacerbation between day 2 and day 7 of admission
Exclusion Criteria:
- Confusion
- Significant hypoxia/unstable medical condition
- Allergy or contraindication to salbutamol and/or ipratropium
- Pneumonia
- Pregnancy
Sites / Locations
- Beaumont Hospital
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Standard hospital jet nebuliser
Vibrating mesh nebuliser
Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a standard hospital jet nebuliser. Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.
Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a vibrating mesh nebuliser (Aerogen Solo) rather than the standard hospital nebuliser Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.